Cargando…
Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins
Nanocarriers have been developed in order to protect drugs or to improve drugs efficiency by reaching the damaged tissue and avoiding systemic and local toxicity. By using HSP90 inhibitors, some cancer drug resistances have been overcome and the loading into nanocarriers of such drugs has shown an i...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
OAE Publishing Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992530/ https://www.ncbi.nlm.nih.gov/pubmed/35582577 http://dx.doi.org/10.20517/cdr.2019.26 |